St. Jude Downplays ICD Scrutiny Impact, But Jury Is Still Out, Analysts Say

During its Jan. 26 earnings call, St. Jude Medical downplayed recent concerns about potential overuse of implantable cardioverter defibrillators as mostly much ado about nothing.